LAZAR S. POPOVIC1,2,*, GORANA MATOVINA-BRKO1, MAJA POPOVIC1,2, KEVIN PUNIE3, ANA CVETANOVIC4,5, MATTEO LAMBERTINI6,7
Oncology Research, Vol.31, No.3, pp. 221-238, 2023, DOI:10.32604/or.2023.028525
Abstract Triple-negative breast cancer (TNBC) is a disease with often an aggressive course and a poor prognosis compared to other subtypes of breast cancer. TNBC accounts for approximately 10%–15% of all diagnosed breast cancer cases and represents a high unmet need in the field. Up to just a few years ago, chemotherapy was the only systemic treatment option for this subtype (1). To date, TNBC is considered a heterogeneous disease. One of the existing classifications is based on the analysis of mRNA expression in 587 TNBC cases, in which Lehman et al. proposed six subtypes of… More >
Graphic Abstract
Login
Register
